2026-01-04 - Analysis Report
Okay, here's a comprehensive analysis of TransMedics Group Inc. (TMDX) based on the data provided:

**1. Return Rate Comparison (TMDX vs. S&P 500 (VOO))**

*   **Company Overview:** TransMedics Group Inc. is a medical technology company pioneering a novel approach to preserve organs for transplant.
*   **TMDX Cumulative Return:** 199.45%
*   **VOO Cumulative Return:** 70.76%
*   **Divergence:**
    *   Current: 128.7
    *   Relative Divergence: 62.2

*   **Analysis:** TMDX has significantly outperformed the S&P 500.  The 128.7 difference in cumulative returns is substantial. The relative divergence of 62.2 indicates that the current difference is in the mid-range of historical divergence between the two. This suggests strong growth and investor confidence in TMDX compared to the overall market.

**Alpha, Beta Analysis:**

| Year       | CAGR    | MDD     | Alpha   | Beta | Cap(B) |
|------------|---------|---------|---------|------|--------|
| 2020-2022  | 94.0%   | 60.2%   | 96.0%   | 1.3  | 2.1    |
| 2021-2023  | 65.0%   | 60.2%   | 64.0%   | 1.7  | 2.7    |
| 2022-2024  | 130.0%  | 51.7%   | 111.0%  | 1.8  | 2.1    |
| 2023-2025  | 120.0%  | 53.4%   | 58.0%   | 1.4  | 4.2    |

*   **CAGR (Compound Annual Growth Rate):** Shows impressive annual growth, particularly in the 2022-2024 period.
*   **MDD (Maximum Drawdown):**  Indicates the potential downside risk. The drawdowns are significant, suggesting relatively high volatility.
*   **Alpha:** Measures the outperformance of TMDX relative to its benchmark. Consistently high alpha figures indicate TMDX is generating returns above what would be expected based on its beta.
*   **Beta:** Measures the stock's volatility relative to the market (S&P 500). A beta above 1 indicates the stock is more volatile than the market. TMDX consistently shows beta values above 1, confirming higher volatility.
*   **Cap(B):**  Implies the market capitalization in Billions.

**2. Recent Stock Price Fluctuations:**

*   **Current Price:** 122.69
*   **Last Market Change:** Up $0.85 from previous close.
*   **5-day SMA:** 122.704
*   **20-day SMA:** 127.454
*   **60-day SMA:** 126.3023

*   **Analysis:** The current price is slightly below the 5-day SMA, significantly below the 20-day and 60-day SMAs. This suggests a recent downtrend in price. The small increase in the last trading day may indicate a potential short-term rebound, but more data is needed to confirm this.

**3. Technical Indicators & Expected Return:**

*   **MRI (Market Risk Indicator):** 0.8 (Medium Investment Recommended)
*   **RSI:** 40.99
*   **PPO:** -0.6448
*   **Hybrid Signal:** Cash_0%_Buy 100% (7 shares - Very Safe - MRI:0.90).  Recommends a 1.2% monthly investment.
*   **Recent Relative Divergence Change:** -3.1 (Indicates short-term decline relative to the comparison index).
*   **Expected Return (%):** 56.4% (Long-term, >2 years)

*   **Analysis:**
    *   The MRI of 0.8 suggests a medium level of risk/reward, indicating that TMDX is considered reasonably safe.
    *   The RSI of 40.99 is below 50, indicating that the stock is not overbought and may have room to run.
    *   The negative PPO suggests that the price is moving down relative to its moving averages.
    *   The hybrid signal is a strong buy recommendation, but this could be a result of backtesting and not a guarantee of future returns.
    *   The negative recent divergence change reinforces the short-term downtrend.
    *   The high expected return (56.4%) is a very positive sign, but remember that it's an estimate based on historical data and algorithms.

**4. Recent News & Significant Events:**

*   **Bullish Sentiment:**
    *   Piper Sandler sees upside from heart trial.
    *   Analyst consensus is "Moderate Buy."
    *   Zacks Investment Research suggests retaining TransMedics stock.
*   **Mixed Sentiment:**
    *   TMDX stock fell despite Q3 earnings beat (Yahoo Finance).
*   **Neutral/Informative:**
    *   TransMedics Group, Inc. (NASDAQ:TMDX) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
    *   Trading the Move, Not the Narrative: (TMDX) Edition - Stock Traders Daily
    *   TransMedics Group Stock (TMDX) Opinions on Recent Insider Sales - Quiver Quantitative

*   **Analysis:** Recent news presents a mixed picture. While analyst ratings and some reports suggest positive future potential, the stock price drop despite earnings beat highlights potential market concerns (possibly related to valuation or future guidance). The insider sales news might warrant further investigation but don't necessarily indicate a negative outlook in isolation. The heart trial update is a key potential catalyst that could drive future growth.

**4-2. Analyst Opinions:**

*   **Consensus:** Buy (Mean: 1.67)
*   **Target Price:**
    *   Average: 144.73
    *   High: 170.00
    *   Low: 114.00

*   **Analysis:** The analyst consensus strongly supports a buy rating. The average target price of 144.73 indicates a significant upside potential (around 18%) from the current price of 122.69. The range of target prices shows varied opinions among analysts, but overall, they are optimistic. There's no recent rating changes.

**5. Comprehensive Analysis (Summary):**

TMDX has demonstrated strong historical outperformance compared to the S&P 500, evidenced by its high CAGR, Alpha, and a substantial divergence in cumulative returns. Analyst ratings are generally positive, with a consensus "Buy" and an average target price suggesting significant upside. The company's technology is a key growth driver and the heart trial is a potential catalyst.

However, there are some cautionary signals. The stock exhibits relatively high volatility (Beta above 1, significant MDD), and recent price action suggests a short-term downtrend. News of a stock price drop despite an earnings beat indicates potential investor concerns.

**Overall Recommendation:**

Based on the provided data, TMDX appears to be a **potentially attractive investment** for investors with a **medium risk tolerance** and a **long-term investment horizon**. The potential for high returns is significant, but the stock's volatility and recent price weakness should be considered.

**Crucial Considerations:**

*   **Do further due diligence:** This analysis is based on the provided data. Investigate the company's financials, competitive landscape, and management team for a more complete picture.
*   **Monitor news and events:** Pay close attention to news regarding the heart trial, earnings releases, and any changes in analyst ratings.
*   **Consider your own risk tolerance:** TMDX is not a low-risk investment. Ensure it aligns with your overall portfolio strategy.


**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.